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Transition from donor candidates to live
kidney donors: the impact of race and
undiagnosed medical disease states
Kidney transplantation is the renal replacement
therapy of choice for end-stage renal disease
(ESRD). Over the last 20 yr, the number of
waitlisted candidates has increased substantially,
with a relatively small increase in the deceased
donor pool (1). As a result, there has been
increasing need for living kidney donors. Access
to living kidney donors has varied among ethnic
groups in part because of differences in waitlist
representation. African Americans (AA) are over-
represented in the ESRD and kidney transplant
waitlist populations (29% and 34%, respectively)
(1, 2), relative to their percentage within the US
population (13%) (3). However, over 70% of
deceased kidney donors are Caucasian (CA).
Differences in the distribution of human leukocyte
antigens (HLA), antibody sensitization and ABO
blood types, these demographic differences often
lead to prolonged deceased donor waiting times for
AA as opposed to other ethnic groups (1).
Despite the growing need, there is a dispropor-
tionately lower rate of live kidney donation among
AA (1). Previous literature has focused primarily
on ethnic differences in living donor willingness,
trust in the health care system and completion of
donor evaluations as reasons for the lower rates of
live kidney donation in AA (4–9). Little attention
has been paid to the possibility that medical
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Abstract: Background: Living kidney donors (LKD) allow for increased
access to lifesaving organs for transplantation. There is a relative paucity of
African American (AA) live kidney donors. The prevalence of medical
disease in LKD candidates has not been well studied. We examined the
medical limitations to living kidney donation in a large Midwestern
transplant center.
Methods: A total of 2519 adults (age ‡ 18 ) evaluated as potential LKD
(PD) between January 1, 1996 and June 30, 2006 were prospectively
followed until evaluation outcome (completed live donation, medical
exclusion from live donation, non-medical exclusion from live donation).
Logistic regression was used to examine the effect of age on donor
exclusion, and chi-square tests were used to compare the likelihood of
donor exclusions between racial and gender groups.
Results: Sixty percent of PD were female (n = 1300), and 86% were
Caucasian (CA) (n = 1862). Overall, 48.7% of PD who underwent
evaluation became LKD. The odds of donation were 52% lower in AA
compared to CA (OR 0.48 p < 0.001). Among PD excluded from dona-
tion, the most common medical diagnoses were hypertension (HTN)
(24.7%), inadequate creatinine clearance (10.6%) and a positive final
crossmatch (10.5%). The rate of PD exclusion for obesity was twofold
higher in AA compared to CA (12.8% vs. 5.8%, p < 0.001).
Conclusions: Hypertension in PD is equally significant barrier to living
kidney donation in AA and CA whereas obesity is a greater barrier in AA.
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contraindications may be a significant barrier to
live donation among AA (10) despite the fact that
AA have a relatively high prevalence of hyperten-
sion (HTN), diabetes mellitus (DM) and obesity
(11, 12), which are disease states that convention-
ally preclude living donation. To evaluate the
impact of medical disease on the likelihood of
successful living kidney donation in AA, we
examined the outcomes of a large cohort of living
donor candidates evaluated at a large academic
medical center in the Midwestern region of the
United States.
Subjects and methods
Study design and patient population
After obtaining University of Michigan Institu-
tional Review Board approval, we prospectively
collected data on all adults (age ‡ 18 ) who
underwent a first-time evaluation as potential
living kidney donors at the University of Michigan
Transplant Center between January 1, 1995 and
June 30, 2006. We stratified subjects by evaluation
outcome and evaluated and compared characteris-
tics of medically acceptable and excluded donor
candidates.
Data sources
Data were obtained from electronic patient records
kept in the Organ Transplant Information System
(OTIS) database as well as the general University
of Michigan Hospital patient care database.
Potential donors were classified according to three
primary outcomes: (i) occurrence of live kidney
donation; (ii) medical exclusion from donation and
(iii) non-medical exclusion from donation. In
instances where more than one potential medical
exclusion diagnosis was documented the primary
investigator reviewed the medical records, includ-
ing interview notes, laboratories and evaluation
meeting minutes to establish the primary reason
for donor exclusion. In the case of multiple
exclusion diagnoses, priority was given to inade-
quate kidney function, followed by HTN and DM
(e.g., a candidate with both HTN and obesity
would have a primary exclusion diagnosis of
HTN).
Demographic and clinical data of potential
donors included serum creatinine, urea nitrogen,
potassium, calcium, phosphorus, glucose, albumin,
alanine aminotransferase, aspartate aminotransfer-
ase, bilirubin, hemoglobin and hematocrit, platelet
count, spot urinalysis and microalbumin/creatinine
ratio, ABO blood type, height, weight, age at
evaluation, race (AA, CA or other), gender, body
mass index (BMI) and relation to intended
recipient. Disease states and medical contraindica-
tions discovered during the donor evaluation
process were collapsed into following categories:
HTN (defined as systolic blood pressure ‡ 140
mmHg or diastolic blood pressure ‡ 90 mmHg, use
of anti-hypertensive medications or 24-h ambula-
tory blood pressure monitor results with > 25% of
readings above 135/85 mmHg in daytime and/or
120/80 in nighttime), DM (abnormal glucose/
abnormal glucose tolerance testing/anti-diabetic
medication use), obesity (operationally a BMI of
‡ 40 kg/m2 or a BMI 30–39 kg/m2 with additional
medical problems), cardiac abnormalities, viral
hepatitis (B and C), kidney abnormalities (protein-
uria, hematuria, nephrolithiasis), inadequate
creatinine clearance (by Cockroft–Gault equation
with iothalamate confirmation as appropriate),
positive final crossmatch, abnormal imaging study
(CT scan or ultrasound) and ‘‘other.’’
Donor evaluation process
In our center, potential donor candidates either
call in by phone or volunteer themselves in person
if they accompany the potential recipient to an
evaluation visit. The donor candidates are asked a
series of screening questions to uncover absolute
and relative contraindications to live kidney
donation (Table 1). Donors without apparent
contraindications to donation have initial ABO
blood typing and tissue typing (cytotoxic [CDC-
AHG] or flow crossmatch in repeat transplant and
sensitized recipient candidates) performed. Com-
patible donors are scheduled for an in-person
comprehensive evaluation visit. All evaluated
candidates are ultimately discussed with our
transplant group in a meeting consisting of neph-
rologists, surgeons, and social workers; transplant
coordinators, HLA lab representatives and finan-
cial coordinators. Donors may be excluded at the
initial meeting (or a future meeting if decision
requires additional studies) and a primary reason
for exclusion is listed in the chart along with other
contributing medical conditions. The primary
exclusion reason is decided by consensus with
the evaluating team.
Study endpoints and statistical analysis
There are three outcomes of the donor candidate
evaluation: (i) live kidney donation; (ii) medical
exclusion from donation and (iii) non-medical
exclusion from donation. Logistic regression was
used to examine the effect of age, race and gender
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on the likelihood of donor exclusion (medical or
non-medical). The effects of age, race and gender
on the BMI and creatinine clearance values were
studied with gamma regression because of the
positively skewed distribution of the observations.
Chi-square estimates were made comparing dona-
tion exclusion rates between racial and gender
groups. Because of small numbers, candidates with
self-identified races other than AA and CA were
excluded from analysis. In addition, candidates
with no race recorded in the medical record were
excluded from analysis. For all analyses, the
statistical significance was set at p value < 0.05.
All analyses were performed using SAS statistical
package, version 9.1 (Institute Inc., Cary, NC,
USA).
Results
Screening survey results for 2006 for donor candi-
dates excluded prior to in-person evaluation were
examined as they represented the most complete
and well-documented records during the study
period. During this period, a total of 93 donors
were screened for 85 recipient candidates. The
intended recipients were primarily CA (67%),
followed by AA (25.9%) and other races (7.1%).
The mean BMI of donors to CA and AA were
similar (29.3 vs. 29.4 kg/m2, respectively). There
were diverse screening exclusions. HTN accounted
for exclusion of 14% of intended donors to CA
and 22.7% of donors to AA. There were no
exclusions for DM and obesity accounted for
exclusion of 7% and 13.6% of donors to CA and
AA, respectively.
There were 2519 individuals who passed the
initial screening survey of medical status and then
presented to the medical center for in-person donor
evaluation. Among all donor candidates evaluated,
2165 were suitable for analysis (Table 2). Evalu-
ated donors excluded from analysis included 300
with no race documented in the medical record, 35
Hispanic, 15 Asian, three Native American and
one bi-racial potential donor. In addition, 13
potential donors had been tentatively approved
as donors, but had not completed donation (0.5%).
The majority of analyzed potential donors were of
female gender and CA race. The overall mean age
of donor candidates was 40.7 (±11.2) yr. AA
donors were over five yr younger on average than
CA donors (p < 0.001) (Fig. 1). The mean BMI of
donor candidates was 27.9 kg/m2 (±5.54) and
ranged from 16.5 to 56.0 kg/m2. Three BMI
outliers (56.0, 54.5, 50.2 kg/m2) were excluded
from the mean calculations to give a more accurate
representation of the overall cohort. Donor BMI
was higher in AA vs. CA candidates (1.05,
p < 0.001), and the distribution of weights was
different between AA and CA candidates (Table 2)
but gender was not significantly associated with
BMI (p = 0.226) in this study population.




Elevated blood pressures or diagnosis of HTN








Gestational HTN, preeclampsia or eclampsia
Gestational diabetes
Cardiac problems or cancers
Other medical problems that may be exacerbated by donation
Table 2. Evaluated donor candidate demographics
Characteristic n (%) p-value
Total donor candidates 2519





Analyzed donor candidates 2165
Female 1300 (60)
Caucasian 1862 (86)
African American 303 (14)
Age, mean, yr ± SD 40.7 ± 11.2
Caucasian 41.5 ± 11.1
African American (reference CA) 35.8 ± 9.9 < 0.001
BMI, mean, kg/m2 ± SD 27.9 ± 5.54
Caucasian 27.7
African American (reference CA) 29.1 < 0.001
kg/m2 Overall CA AA
BMI distribution, mean, percent
< 20 11.7 11.4 13.5 0.281
20–24.9 26.8 27.8 20.5 0.007
25–29.9 33.9 34.2 31.7 0.389
‡ 30 27.7 26.6 34.2 0.005




*BMI, body mass index.
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Overall, 48.7% of donor candidates were suc-
cessful (Table 3). Male and female candidates were
equally successful as donors (p = 0.112) but AA
were only half as likely as CA to become donors
(p < 0.001). The odds of medical donor exclusion
increased by 2% with each year of increasing age
(Fig. 2). Estimated creatinine clearance did not
differ by race (p = 0.623), but was 9% lower in
female (0.91 compared to male, p < 0.001) donor
candidates. The mean serum creatinine values in
AA donor candidates were 5% higher than that of
CA donor candidates (p < 0.001) (Fig. 3).
Among donor candidates excluded for medical
reasons, the most common diagnoses overall were
HTN (24.7%), followed by inadequate creatinine
clearance (10.6%) and a positive final crossmatch
(10.5%) (Table 4). HTN was equally prevalent in
excluded AA and CA donors (22.6% and 25.1%,
respectively, p = 0.434); however, in excluded AA
donors, the second most frequent exclusion diag-
nosis was obesity (12.8%), which was twofold
higher than the rate of exclusion for obesity among
CA (5.8%). Donor candidates excluded for obesity
had higher mean BMI values than the overall
Fig. 1. Density of age distribution by race. African American
(black line) and Caucasian (gray line).
Table 3. Evaluated donor candidate outcomes
Characteristic N
OR (point
estimate) OR (95% CI) p-value
Excluded from donation 1350 (53.6)
Completed donation 1156 (45.9)
Incomplete evaluations 13 (0.8)
Odds of completed donation
Female
(reference = male)
0.87 (0.73, 1.03) 0.112
AA (reference CA) 0.48 (0.37, 0.62) < 0.001
Donation by increasing
year of age
0.98 (0.97, 0.99) < 0.001
Age categories
(reference 18–44)
45–64 0.68 (0.58, 0.82) < 0.001
65+ 0.38 (0.12, 1.05) < 0.072
Estimated creatinine clearance
AA (reference CA) 0.993 (0.96, 1.02) 0.623
Female
(reference = male)
0.91 (0.89, 0.93) < 0.001
Serum creatinine
AA (reference CA) 1.072 (1.05,1.10) < 0.001
Fig. 2. Plot of frequency of donation vs. age by race. African
American (black line), Caucasian (gray) and overall (dashed).
Fig. 3. Density of distribution of serum creatinine for African




cohort (40.1 kg/m2 and 41.4 kg/m2 in AA and CA,
respectively). There was some overlap in catego-
ries, with 9.3% of candidates excluded for HTN
also having an obese BMI.
Overall, AA had a higher frequency of non-
medical exclusion than CA candidates (Table 4).
The most frequent reason donor candidates were
excluded for a non-medical reason was the
intended recipient received a deceased donor
transplant (27.1%). The second and third most
frequent non-medical exclusion reasons were re-
cipient death (18.6%) and donors being lost to
follow up (15%).
We examined era effects for the most common
donor exclusions comparing donors evaluated
January 1, 1995 through December 31, 2000 (era 1)
with those evaluated January 1, 2001 through June
30, 2006 (era 2) (Table 5). The overall rate of
exclusion increased from 44.4% in era 1 to 56.7%
in the most recent era (p < 0.001). Among donor
candidates excluded for medical reasons, we found
that the rates of exclusion for HTN decreased
between eras from 32.6% to 20.6% (p < 0.001).
The frequency of exclusion for inadequate kidney
function increased (4.9% to 13.7%, p < 0.001),
and there were no significant differences in exclu-
sion for positive crossmatch and obesity between
eras. The overall serum creatinine values declined
slightly between eras (0.92 to 0.89 mg/dL,
p < 0.001) but were significant only in CA. The
mean Cockroft–Gault creatinine clearance was
slightly higher in the current era (116.5 vs.
112.3 mL/min, p = 0.008) and was increased for
both AA and CA candidates (Table 5). Iothala-
mate GFR determinations were made in 10 candi-
dates who successfully donated (1 AA) and three
candidates who were ultimately excluded for low
GFR (1 AA). All iothalamate GFRs were mea-
sured in the current era.
Discussion
In 2001, the number of live kidney donors
surpassed deceased donors in the United States
(1). Live kidney donation increased 73% in the
period from 1997 through 2004, with only a small
decline since that time. Currently, the largest
growth of live kidney donation is from biologically
unrelated donors who account for 36% of all live
donors (1). However, most of the growth in live
kidney donation has been limited to CA donors
even though AA and other racial minorities are
disproportionately over-represented among ESRD
patients awaiting kidney transplantation. As access
to living kidney donation is not governed by an
allocation system, the ability to receive a live donor
kidney transplant is determined by the transplant
candidates being able to find relatives and non-
relatives who could step forward as potential
donor candidates. According to US census data,
the average family size and number of sibships is
larger for AA and Hispanic individuals compared
to CA (13). At the same time, AA and Hispanic
individuals have a higher prevalence of medical
conditions that often preclude them from being
donor candidates such as HTN, obesity and DM
(11). Thus, the impetus for the current study was to
determine whether these medical contraindications
disproportionately affect potential AA donors who
have passed an initial medical screening and have
Table 4. Frequency of major donor exclusions
AA CA p-value
Medical donor exclusion (%)
HTN 22.6 25.1 0.43
Diabetes mellitus 1.96 3.77 0.36
Obesity 12.75 5.75 0.01
Cardiac abnormalities 0.98 3.95 0.13
Viral hepatitis (B and C) 6.86 4.13 0.22
Kidney abnormalities 6.86 10.05 0.31
Inadequate renal function 10.78 10.59 0.95
Final crossmatch positive 9.80 10.59 0.81
Abnormal imaging study 1.96 6.28 0.08
Other 25.45 19.79 0.12
Non-medical donor exclusion (%)
Overall frequency of exclusion 46.88 38.59 0.003
IR received DD Txp 28 23.3 0.37
IR received LD Txp 4 2.2 0.42
IR death 19.7 14.4 0.25
DC lost to follow up 13.4 21.1 0.07
DC changed mind 8.9 13.3 0.20
Other 26.29 26.67 0.942
Table 5. Donor outcome by era of evaluation
Era
1995–2000 2001–2006 p-value
Donor exclusion frequency (%)
Overall 44.4 56.7 < 0.001
HTN 32.6 20.6 < 0.001
Inadequate renal function 4.9 13.7 < 0.001
Final crossmatch positive 8.4 11.6 0.20
Obesity 6.2 7.2 0.63
Serum creatinine, mean, mg/dL ± SD
Overall 0.92 ± 0.197 0.89 ± 0.173 < 0.001
CA 0.91 ± 0.196 0.88 ± 0.170 < 0.001
AA 0.96 ± 0.198 0.94 ± 0.182 0.415
Creatinine clearance, mean, mL/min ± SD
(Cockroft–Gault estimate)
Overall 112.3 ± 32.50 116.5 ± 33.15 0.008
CA 112.3 ± 32.40 115.8 ± 32.57 < 0.001
AA 110.8 ± 33.21 121.5 ± 36.52 0.025
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presented for a more comprehensive in-center
donor evaluation. Consistent with national data,
our donor candidates were primarily female and
CA (1). We found that AA donor candidates who
entered the in-center donor evaluation process
were only 48% as likely as CA to become donors.
We also found that AA donor candidates had a
younger age distribution than CA candidates,
perhaps reflecting the younger median age of
ESRD in the AA population (2), and the tendency
of most donors to be immediate relatives, spouses
and peers. Our findings have significant implica-
tions for access to living kidney donation as it
shows that unwillingness to come forward as
donors may not be the most important limiting
factor for live donor transplant AA recipient
candidates.
Despite a prior telephone screening with specific
questions about HTN, DM, obesity and other
commonly accepted medical contraindications to
live donation, our study showed that a new
diagnosis of HTN was established at an alarming
25% of evaluated donors, which is similar to the
prevalence of HTN (29%) in the general adult
population (11, 12, 14). The finding is particularly
concerning as a number of hypertensive individuals
were excluded by the telephone screening. Because
AA in the general population have a higher
prevalence of HTN compared to CA (41% vs.
28%) (11, 15) and that AA also have an earlier
onset of HTN (16, 17), we would have expected
that new diagnosed HTN would be more common
in AA potential donors compared to CA. To the
contrary, we found a similar rate of newly
diagnosed HTN in both AA and CA (22.6% and
25.1%, respectively). However, although the fre-
quency of HTN was similar, AA donor candidates
were significantly younger than CA, consistent
with the earlier onset of HTN often seen in AA.
Our screening data did suggest increased HTN
exclusions among screened AA potential donors,
but the small numbers, lack of complete screening
information and lack of direct knowledge of donor
race limited our conclusions. The increasing inci-
dence and earlier age of onset of HTN in the
general population portends even a greater limita-
tion for the living kidney donor pool in the United
States As AA have a disproportionate prevalence
of HTN in the general population, the impact on
living kidney donation may be especially detrimen-
tal to this group.
We found that AA were more likely to be
excluded for obesity compared to CA. Our finding
is consistent with the higher prevalence of obesity
in AA compared to CA individuals (11), but it also
reflects that donor candidates did not recognize
themselves as obese because the initial pre-evaluation
screening included questions about weight and
obesity which these potential donors were required
to answer negatively before an in-center donor
evaluation was scheduled. Among evaluated do-
nors eventually excluded for obesity, 50% of CA
and 38% of AA donors ideally should have been
excluded by telephone screening for BMI > 40 kg/
m2. With better screening exclusion, we would have
seen an even larger tendency for AA exclusion for
obesity than we documented. Our findings appear
to reflect underreporting on the part of screened
candidates. We cannot determine whether the
underreporting was deliberate or unintentional.
Our findings are consistent with the documented
tendency for individuals to underestimate their
weight and overestimate their height when sur-
veyed (18). In a positive light, the high rate of
obesity among evaluated potential donors may
reflect a high degree of motivation to become
donors despite being overweight.
As a practice, we have evaluated donor candi-
dates as they are at the time of the evaluation. We
specifically have not requested weight loss for the
purpose of donation nor do we contract with
donors for them to maintain a weight after
donation. We are aware of the high recidivism
rate in individuals who lose weight (19) and feel
that using such donors at what may be an artificial
nadir of their weight is not in their best interest.
Consistent with this practice, for donors who
report historic obesity, we usually expect to see
an acceptable weight maintained for a least one yr
prior to the evaluation. It is not clear whether our
approach has any implications on donor accept-
ability by race, but our practice may result in
overall more exclusion for obesity than in other
centers.
The issue of overweight and obese donor candi-
dates is of particular importance given the negative
metabolic impact of obesity. Increasing BMI has
been consistently shown to increase the risk of
HTN (20), DM, and hyperlipidemia, overall
increasing the risk of cardiovascular death in
overweight individuals (21). Interestingly, in-
creased BMI has not been consistently found to
directly contribute to increased risk of chronic
kidney disease (CKD) (22). However, increasing
waist-to-hip ratios (WHR) have been positively
associated with increased CKD risk and cardio-
vascular death (23, 24). Waist circumference (WC)
and WHR have not been well studied in living
donor candidates, but appear to differ among races
and be better predictors for metabolic abnor-
malities than BMI alone (25, 26). In addition,
the weight of live donor candidates considered
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acceptable for donation varies widely by transplant
center (25–27). There is evidence from the general
population that young age, small WC and AA race
are associated with decreased likelihood of meta-
bolic abnormalities being associated with an obese
BMI (28). As a result, simple BMI measurements
are unlikely to fully describe our candidates
metabolic risk profiles and with a more compre-
hensive description, perhaps some of the excluded
AA candidates would be found acceptable for
donation. In our center, we historically have not
measured WHP ratios in our donor candidates, but
WHR and other such anthropomorphic measures
as percent body fat, assessment of visceral adipose
and abdominal subcutaneous tissue and weight–
height ratios will be important for future stratifi-
cation of metabolic risk in live donor candidates.
Age was a significant factor in candidate appro-
priateness for donation, with the overall likelihood
of donor exclusion increasing by 2% per year of
donor age. Our finding is particularly important
given the demographics of the ESRD and recipient
candidate population. Individuals over age 64
make up the fastest growing group of ESRD
patients and constitute 17% of currently waitlisted
recipient candidates (1). The majority of live
donors are spouses, siblings and parents of recip-
ients. As donors and recipients age, there may be a
significant decrease in access to live kidney donors
because of medical exclusion. We may see in-
creased pressure on the deceased donor system for
recipient candidates with decreased live kidney
donor access. Interestingly, age seemed to have a
bigger impact on AA than CA likelihood of
successful donation. The difference is unexpected
and may be an artifact of having a number of
young AA donor candidates.
Low estimated renal function was a cause for
medical exclusion in over 10% of donor candi-
dates. The frequencies were similar in AA and CA
candidates. Our findings potentially highlight and
reflect the lack of awareness of kidney disease and
kidney disease risk in the US population. In our
study, AA candidates had higher serum creatinine
values but clinically equivalent creatinine clear-
ance. The AA mean creatinine clearance values
appeared to increase over the course of the study,
but not by a clinically meaningful amount.
Throughout the study period, we utilized Cockroft–
Gault calculations of creatinine clearance as our
primary estimator of renal function. We used
iothalamate measures rarely during the study,
and only in the current era. In our center, the use
of isotopic measures has historically been used to
rule in otherwise acceptable candidates with low
calculated clearance (usually slim females) rather
than to rule out candidates. There is a potential for
overestimation of renal function in our donor
candidates such that we may be accepting higher
risk candidates inadvertently. Inadequate donor
kidney function poses a challenge for the future, as
increasing age, HTN and obesity play a role in
renal dysfunction, and more routine use of isotopic
measures may be necessary (12, 29, 30).
The analysis of era effects on likelihood of live
donation revealed an overall significant increase in
the likelihood of a donor candidate being excluded
for medical reasons in the most recent era studied.
Although the increased donor exclusions could be
attributed to changes in the health of donor
candidates in general, the results suggest somewhat
different explanations. Interestingly, the likelihood
of exclusion for HTN actually decreased in the
recent era compared to earlier evaluations. Less
HTN exclusions are probably not the result of
healthier donors (as HTN prevalence has increased
between the eras analyzed), but rather the result of
more effective donor candidate screening prior to
evaluation.
The largest increase in donor exclusions between
the two eras studied for both AA and CA was
among candidates with inadequate renal function.
Our exclusion criteria (estimated creatinine clear-
ance ‡ 80 mL/min) did not change during the eras.
However, we have increasingly utilized more
accurate measures of renal function (i.e., iothala-
mate) in our donor candidates, so we may be
excluding candidates who previously would have
been allowed to donate. The effect may have been
more pronounced in AA given the higher BMIs
and the resultant increase in creatinine clearance
when using the Cockroft–Gault equation. We have
not used the modification of diet in renal disease
(MDRD) calculation in our donor candidates, as
the MDRD tends to underestimate true kidney
function in individuals without kidney disease. We
cannot exclude the possibility that as the need for
living donors has increased that we have been
seeing candidates with increasingly marginal kid-
ney function. In the future, consistently utilizing
iothalamate or a similar method will enhance our
ability to determine the true trends in donor
candidate kidney function.
The rate of donor exclusion for both positive
final crossmatch and obesity did not increase over
the study period. We know that during the study
period that the US population as a whole has had a
significant increase in obesity prevalence. Our
donor candidates, however, remain a selected,
relatively healthy population with seemingly low
obesity rates. A small number of our candidates
were obese, but had a more prominent medical
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condition (HTN), which was their primary cause of
exclusion. Certainly, the frequency of donor exclu-
sion underestimates the prevalence of obesity in
our donor population. At the same time, the
concern that increasingly obese donor candidates
were being accepted for donation is not strongly
supported by our data.
During the study period, there was a trend
toward more CA candidates than AA being lost to
follow up. Our results are in contrast to the
findings of both Lunsford (31) and Reeves-Daniel
(32), who found AA more likely to be lost to follow
up. AA showing a greater interest in live donation
than CA would directly contradict much of the
literature suggesting a lack of interest among AA
to donate. Loss to follow up was not a primary
focus of our study, and the overall number of
donor candidates in our study limits our conclu-
sions. In addition, there are many socioeconomic
and cultural issues not addressed by our study that
could impact the likelihood of follow through with
donor evaluation. In the future, deliberate evalu-
ation of patient, provider or center factors that
may improve donor follow through in general and
AA donation specifically could be important to
expanding the donor pool.
Our transplant center is located in the south-
eastern part of Michigan. Fourteen percent of
donors evaluated over the study period were AA.
Our AA potential donor population was consistent
the US population representation of 13% (and the
Michigan population of 14%) (3), although falling
short of the waiting list (34%) representation. The
significant numbers of AA individuals volunteer-
ing as donor candidates highlights the willingness
on the part of AA to donate, although the
proportion of donors does not meet the recipient
candidate need. Our study suggests that a signif-
icant limiting factor to living kidney donation is
donor medical disease and supports the data
generated by Lunsford and colleagues (31). From
a policy standpoint, our findings indicate a need to
focus efforts not just on encouraging donation, but
on educating the population on medical contrain-
dications to donation to help select the most
appropriate cohort of donor candidates. Our study
also highlights the complex nature of the shortage
of donor organs, as previously discussed by Young
and colleagues (33). Furthermore, the results of
these study points to high reservoir of unrecog-
nized potentially serious medical illnesses in a
relatively young cohort of candidates who consid-
ered themselves ‘‘healthy’’ and it shows that
educational awareness about kidney disease,
HTN and obesity has not penetrated to all relevant
segments of the society.
We found a high frequency of donor exclusion
resulting from the intended recipient receiving a
deceased donor transplant. Although initially
counter-intuitive, such a finding accurately reflects
our patient population. Many if not most of our
candidates do not have a live donor candidate at
the time of recipient evaluation. A number of our
waitlisted candidates look for years before having a
potential candidate who volunteers and makes it
through the initial screening. In addition, many of
our candidates are reluctant to accept a live donor
initially and only consider one after significant time
on dialysis or after suffering medical complica-
tions. We see this not uncommonly, particularly
when the potential donors are likely to be a
recipients children.
In our program, HTN,DM, CrCl< 80 mL/min,
current pregnancy, ischemic heart disease, chronic
NSAID therapy, active infection and active malig-
nancy are and were absolute contraindications to
donation throughout the study period. We have
increasingly utilized iothalamate measurements in
selected donors (usually thin females) who were
thought to likely be acceptable, usually finding true
renal function that is above our cutoff. Over the
study period understanding of HTN and consensus
HTN recommendations (JNC-7) have likely low-
ered our threshold for exclusion on that basis. In
addition, the increased availability of 24-h ambu-
latory blood pressure monitoring has added to our
accuracy in detecting subclinical HTN.
One of the most surprising findings was that 300
individuals had no race data available. In our
screened candidates, we expect this as we do not
ask for race. However, in those who appear for
evaluation, the lack of race data reveals multiple
factors at work. We looked for race data among
the patient demographics captured at the time of
patient registration, among the nephrology, sur-
gery and social work notes generated as part of the
evaluation and in the minutes of the evaluation
team meetings. To have no race data means that
information was absent in all five places. The
finding is most interesting because a number of
these individuals successfully donated. Perhaps
excess political correctness led us to not dictate
race in our notes. At the same time, the donor
candidates themselves had to choose to leave race
off of their registration forms. This was allowable
as many of the data elements, including race and
religion, are optional. The absence of this infor-
mation perhaps exposes a discomfort among both
patients and providers with race information that
is worthy of additional examination.
This was a registry study, so we were limited to
information in the database. Small numbers of
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older donors and other ethnicities limit interpreta-
tion. Our donor population may have changed
over the study period in ways not appreciated by
our analysis that may influence our results. We did
not measure WHP ratios or other anthropomor-
phic measures that would help to better describe
the metabolic risk profiles of our donor candidates.
In addition, we were unable to report on the
demographic and medical disease distribution of
all volunteer donor candidates. Our donor screen-
ing forms do not capture race data. In addition, as
our donor screening forms were developed for
clinical not research purposes, historically there
has not been accurate tracking of donors excluded
by screening. Our screening data presented are
consistent with our more recent experience, but
nevertheless the lack of complete data over the full
study period does leave the question of screening
exclusion frequency incompletely answered.
Conclusion
A plethora of treatable medical disorders go unrec-
ognized in a significant proportion of Americans in
the middle age and older age groups. HTN and
obesity (major impediments to live kidney donation)
shrink the potential living kidney donor pool by
more than one-third of all US adults. These medical
barriers to donation have a disproportionately





This article has not been published previously in whole or
in part, except in abstract form.
The authors declare that there are no financial supports
or conflict of interest.
References
1. 2007 Annual Report of the U.S. Organ Procurement and
Transplantation Network and the Scientific Registry of
Transplant Recipients: Transplant Data 1996–2006. In:
Health Resources and Services Administration HSB.
Rockville, MD: Division of Transplantation.
2. U.S. Renal Data System. USRDS 2007 Annual Data
Report: Atlas of Chronic Kidney Disease and End-Stage
Renal Disease in the United States. In: Census US, ed.
Bethesda, MD: National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases,
2007.
3. Profiles of General Demographic Characteristics, 2000,
Census of Population and Housing. 2001.
4. Monet T, Pullen-Smith B, Haisch C, Ensley D, Royal
R. Living renal donation in the African-American com-
munity. Transplant Proc 1997: 29: 3649.
5. Hidalgo G, Tejani C, Clayton R et al. Factors limiting
the rate of living-related kidney donation to children in an
inner city setting. Pediatr Transplant 2001: 5: 419.
6. Shilling LM, Norman ML, Chavin KD et al. Health-
care professionals perceptions of the barriers to living
donor kidney transplantation among African Americans.
J Natl Med Assoc 2006: 98: 834.
7. Trollinger J, Flores J, Corkill JK, Ryan R, Light
JA. Increasing living kidney donation in African Ameri-
cans. Transplant Proc 1997: 29: 3748.
8. Rodrigue JR, Cornell DL, Lin JK, Kaplan B,
Howard RJ. Increasing live donor kidney transplantation:
a randomized controlled trial of a home-based educational
intervention. Am J Transplant 2007: 7: 394.
9. Boulware LE, Ratner LE, Sosa JA, Cooper LA,
LaVeist TA, Powe NR. Determinants of willingness to
donate living related and cadaveric organs: identifying
opportunities for intervention. Transplantation 2002: 73:
1683.
10. Tankersley MR, Gaston RS, Curtis JJ et al. The living
donor process in kidney transplantation: influence of race
and comorbidity. Transplant Proc 1997: 29: 3722.
11. National Center for Health Statistics. Health,
United States, 2007 With Chartbook on Trends in the
Health of Americans. Hyattsville, MD: U.S. Government
Printing Office, 2007.
12. Chobanian AV, Bakris GL, Black HR et al. Seventh
report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure. Hypertension 2003: 42: 1206.
13. Bureau USC. Current Population Survey Reports, Fam-
ilies and Living Arrangements, March 2006. http://
www.census.gov, Accessed April 2008; 2006.
14. Calhoun DA, Jones D, Textor S et al. Resistant
Hypertension: Diagnosis, Evaluation, and Treatment. A
Scientific Statement From the American Heart Association
Professional Education Committee of the Council for High
Blood Pressure Research. Hypertension. 2008: 51: 1403.
15. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension
Awareness, Treatment and Control-Continued Disparities
in Adults: United States, 2005–2006. National Center
for Health Statistics Data Brief No. 3. Hyattsville, MD:
National Center for Health Statistics 2008: 51: 1403.
16. Hajjar I, Kotchen TA. Trends in prevalence, awareness,
treatment, and control of hypertension in the United
States, 1988-2000. JAMA 2003: 290: 199.
17. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G.
Heart failure in the general population of men–morbidity,
risk factors and prognosis. J Intern Med 2001: 249: 253.
18. Johnson WD, Bouchard C, Newton RL Jr, Ryan DH,
Katzmarzyk PT. Ethnic differences in self-reported and
measured obesity. Obesity (Silver Spring) 2009: 17: 571.
19. Wing RR, Phelan S. Long-term weight loss maintenance.
Am J Clin Nutr 2005; 82(1 Suppl):222S.
20. Gelber RP, Gaziano JM, Manson JE, Buring JE, Sesso
HD. A prospective study of body mass index and the risk
of developing hypertension in men. Am J Hypertens 2007:
20: 370.
21. Caprio S, Daniels SR, Drewnowski A et al. Influence of
race, ethnicity, and culture on childhood obesity: impli-
cations for prevention and treatment: a consensus state-
ment of Shaping Americas Health and the Obesity
Society. Diabetes Care 2008: 31: 2211.
Medical barriers to live kidney donation
9
22. Foster MC, Hwang SJ, Larson MG et al. Overweight,
obesity, and the development of stage 3 CKD: the Fra-
mingham Heart Study. Am J Kidney Dis 2008: 52: 39.
23. Elsayed EF, Sarnak MJ, Tighiouart H et al. Waist-to-
hip ratio, body mass index, and subsequent kidney disease
and death. Am J Kidney Dis 2008: 52: 29.
24. Elsayed EF, Tighiouart H, Weiner DE et al. Waist-to-
hip ratio and body mass index as risk factors for cardio-
vascular events in CKD. Am J Kidney Dis 2008: 52: 49.
25. Perry A, Wang X, Kuo YT. Anthropometric correlates
of metabolic syndrome components in a diverse sample of
overweight/obese women. Ethn Dis 2008: 18: 163.
26. Lee S, Kuk JL, Hannon TS, Arslanian SA. Race and
gender differences in the relationships between anthropo-
metrics and abdominal fat in youth. Obesity (Silver
Spring) 2008: 16: 1066.
27. Davis CL, Delmonico FL. Living-donor kidney trans-
plantation: a review of the current practices for the live
donor. J Am Soc Nephrol 2005: 16: 2098.
28. Wildman RP, Muntner P, Reynolds K et al. The obese
without cardiometabolic risk factor clustering and the
normal weight with cardiometabolic risk factor clustering:
prevalence and correlates of 2 phenotypes among the US
population (NHANES 1999–2004). Arch Intern Med
2008: 168: 1617.
29. Kambham N, Markowitz GS, Valeri AM, Lin J,
DAgati VD. Obesity-related glomerulopathy: an emerg-
ing epidemic. Kidney Int 2001: 59: 1498.
30. Molenaar EA, Hwang SJ, Vasan RS et al. Burden and
rates of treatment and control of cardiovascular disease
risk factors in obesity: the Framingham Heart Study.
Diabetes Care 2008: 31: 1367.
31. Lunsford SL, Simpson KS, Chavin KD et al. Racial
disparities in living kidney donation: is there a lack of
willing donors or an excess of medically unsuitable can-
didates? Transplantation 2006: 82: 876.
32. Reeves-Daniel A, Adams PL, Daniel K et al. Impact of
race and gender on live kidney donation. Clin Transplant
2009: 23: 39.
33. Young CJ, Gaston RS. Renal transplantation in black
Americans. N Engl J Med 2000: 343: 1545.
Norman et al.
10
